Compare Amphastar Pharmaceuticals Inc (AMPH) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs MINISO Group Holding Ltd — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while MINISO Group Holding Ltd trades at $11.47 (market cap $3.51B). The key difference: MINISO Group Holding Ltd is far larger — about 4.2× Amphastar Pharmaceuticals Inc's market cap, and MINISO Group Holding Ltd pays a 5.65% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | MNSO | |
|---|---|---|
Market Cap | $826.08M | $3.51B |
Sector | Health | Technology |
52-Week High | $30.81 | $26.63 |
52-Week Low | $16.87 | $11.30 |
Enterprise Value | $1.22B | $4.17B |
Dividend Yield | — | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
MNSO trades at $11.79, up 2.79% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q1 2026 earnings, beating expectations with EPS of $0.591, and announced a HK$2 billion share repurchase program on June 29, 2026. Revenue grew to $21.44 billion in 2025, with a net income margin of 8.98% and a P/E ratio of 12, indicating potential undervaluation.
The outlook is mixed: analyst consensus is 75% buy with growth potential from overseas expansion, but risks include margin compression and recent earnings misses. The stock's current price near the lower end of its 52-week range suggests caution amid bearish technical trends, though fundamentals support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
